格隆汇8月26日｜寒武纪跌逾3%，成交额超100亿元。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

"随着杰克逊霍尔会议落幕，下一个重要催化剂就是英伟达的财报。"DataTrek Research联合创始人Nicholas Colas指出。由于英伟达在标普500指数中的权重接近8%，其走势对大盘影响巨大，"英伟达的表现可能会 压过甚至放大鲍威尔讲话后的市场反应。" 目前英伟达市值已超过4万亿美元，其股价今年以来已累计上涨近34%，远超标普500指数9.5%的涨幅。技 术面上，分析师关注的关键点位包括50日均线约167美元和短期阻力位184美元。 美国股市本周将迎来"重量级考验"，人工智能芯片巨头英伟达(NVDA.US)将在周三盘后公布财报，市场普 遍认为其业绩与前景展望将成为决定大盘下一步走向的关键因素。 在美联储主席鲍威尔上周五于杰克逊霍尔年会上暗示9月可能降息后，美股一度强劲反弹，标普500指数上 周五收涨1.5%，并录得周涨幅0.3%。然而，周一市场未能延续涨势，标普500指数收跌0.43%，道琼斯工业 指数下挫0.77%，纳斯达克综合指数回落0.22%。 与此同时，作为"七巨头"之一的英伟达也是最后一个公布季度业绩的科技巨头。Ameriprise Financial首席市 场策略师Anthony S ...

每经AI快讯，8月25日，寒武纪-U成交额达200亿元，现涨3.69%。 （文章来源：每日经济新闻） ...

Core Points - The EU and the US announced a new trade agreement detailing tariffs and market access, with the US imposing a 15% tariff on most EU goods while exempting certain products [1] - The EU committed to eliminating tariffs on US industrial goods and providing preferential market access for US seafood and agricultural products [1] - The EU plans to purchase $750 billion worth of US liquefied natural gas, oil, and nuclear products by 2028, along with $40 billion in US AI chips [1][2] Group 1 - The US will impose a 15% tariff on most EU imports, while certain natural resources, aircraft, and generic drugs are exempt [1] - The EU will eliminate tariffs on US industrial products and provide preferential access for US seafood and agricultural goods [1] - The EU aims to significantly increase its procurement of US military and defense equipment [1] Group 2 - The agreement has raised concerns about fairness, with critics arguing it disproportionately favors the US [4][8][16] - There are unresolved issues regarding steel and aluminum tariffs, with no clear solution provided in the agreement [9] - The digital regulatory divide remains a significant point of contention, with no substantial progress made in this area [11] Group 3 - The agreement has been described as a "terrible, complete surrender" by some EU officials, highlighting the lack of reciprocity [8] - Concerns have been raised about the potential negative impact on European growth and employment due to the perceived imbalance in the agreement [16] - The agreement lacks legal binding, raising questions about its long-term viability and enforcement [20][23] Group 4 - The EU is expected to initiate legislation to ensure the US commits to reducing auto tariffs retroactively [23] - The agreement is seen as a "loss control document" for the EU, reflecting its dependency on the US [23][25] - Future negotiations are anticipated to address a fair and balanced trade agreement, although skepticism remains about the EU's leverage [25]

前段时间，中国财富500强，热腾腾的出炉，各大公司被亮出家底。 前几天，又一重磅榜单发布，世界500强排行榜来了！ 这次被亮家底的，不再只是某个大公司，而是彰显了各个国家真正的经济实力。 想象一下，全球经济的血液，高达41.7万亿美元的财富洪流，正被一张无形的榜单精准分流。 | 揭示全球最大企业的最新发展趋势。 | 每页显示 | v 条记录 | | | 关键字 | | --- | --- | --- | --- | --- | --- | | 2025-07-29 | 排名 ^ > | 公司名称 ℃ | 营业收入 ℃ | 利润 ○ = | 国家 | | | | (中文) | (百万美元) | (百万美元) | | | | 1 | 沃尔玛(WALMART) | 680,985 | 19.436 | 美国 | | 财富中文网于北京时间2025年7月29日与全球同步发布了 | | | | | | | 最新的《财富》世界500强排行榜。依据这个榜单的数 | 2 | 亚马逊 (AMAZON.COM) | 637.959 | 59.248 | 美国 | | 据,人们可以了解全球大型企业的最新发展趋势,深入到 | | | ...

格隆汇8月22日｜寒武纪(688256.SH)20CM涨停，股价报1243.2元，为A股市场第二高价股，仅次于贵州茅台，且距贵州茅台(1461元)股价仅差218元。寒 武纪年内累涨89%，最新市值升破5200亿元。 股市慢牛来了，你准备好了吗？备好账户跟进牛市，更有五大福利领取>> ...

每经AI快讯，8月22日，寒武纪涨停，市值近5200亿元，股价报1243.20元，距贵州茅台股价仅差近200 元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The stock price of Cambrian Biologics has risen over 4% on August 21, reaching a historical high and a market capitalization of 440 billion CNY [1]. Group 1: Stock Performance - Cambrian Biologics' stock price increased by 7.06% with a trading volume of 6.359 billion CNY [2]. - The stock opened at 1020.00 CNY, with a highest price of 1066.00 CNY and a lowest price of 1005.57 CNY, resulting in a trading amplitude of 5.97% [2]. - The total market value of Cambrian Biologics is reported to be 441.4 billion CNY, with a circulating market value of 441.4 billion CNY [2]. Group 2: Financial Metrics - The earnings per share (EPS) for Cambrian Biologics is 0.31, with an estimated EPS of 3.87 for 2025 [2]. - The total share capital is 418 million shares, with a free float of 203 million shares [2]. - The price-to-earnings ratio (P/E) is reported at 3400, while the price-to-book ratio (P/B) stands at 74.87 [2].

Group 1 - The stock price of Cambrian has surpassed 1000 yuan, marking a new historical high [1] - Cambrian's stock has increased by nearly 10% [1]

Group 1 - The stock of Cambrian Biologics-U (688256.SH) surged nearly 10%, reaching 1027 yuan, and once again broke the 1000 yuan mark, setting a new historical high [1] - The market capitalization of the company is approaching 430 billion yuan [1] - The stock has increased by 56% year-to-date [1]